Evidence map›Paper›PMID 39247196›Full record

ArticleFrontiers in immunology2024

Zinc dampens antitumor immunity by promoting Foxp3

Sugandha Narayan, Rajdeep Dalal, Zaigham Abbas Rizvi, Amit Awasthi

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Genes · 2025
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sugandha NarayanCentre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, National Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India.
Rajdeep DalalCentre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, National Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India.
Zaigham Abbas RizviCentre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, National Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India.
Amit AwasthiCentre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, National Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The role of zinc (Zn) in tumor development and immune modulation has always been paradoxical. This study redefines our understanding of the impact of Zn on cancer progression and therapeutic strategies. Methods: We investigated the effects of dietary Zn levels on tumor progression and immune responses. This included examining the impact of both high and deficient dietary Zn, as well as Zn chelation, on tumor growth and immune cell populations. Specifically, we analyzed the frequency of Foxp3 Results: Our findings show that high dietary Zn promotes tumor progression by fostering a protumorigenic environment mediated by T cells. Increased Zn intake was found to facilitate tumor progression by increasing Foxp3 Discussion: These results reveal a novel mechanistic insight into how Zn influences tumor progression and immune regulation. The identification of FOXO1 as a key regulator opens new avenues for understanding the role of Zn in cancer biology. Furthermore, we introduce a promising therapeutic approach by showing that administering clioquinol (CQ) significantly enhances

Indexed as

Forkhead Transcription FactorsT-Lymphocytes, RegulatoryZincAnimalsCell Line, TumorClioquinolFemaleForkhead Box Protein O1HumansImmunotherapyMelanomaMelanoma, ExperimentalMiceMice, Inbred C57BLTumor MicroenvironmentClioquinolForkhead Box Protein O1Forkhead Transcription FactorsFoxo1 protein, mouseFoxp3 protein, mouseZincantitumor immunitycancercheckpoint inhibition therapyFOXO1PD-1regulatory T cellzinc

Identifiers

PMID39247196
PMCPMC11377231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.